surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университет10.35266/2304-9448-2023-2-26-33surgumed-650Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНА. ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕCLINICAL MEDICINE. ORIGINAL RESEARCHSARS-COV-2 – НОВЫЙ ФАКТОР РИСКА РАЗВИТИЯ ПРЕЭКЛАМПСИИSARS-COV-2 IS A NEW RISK FACTOR FOR PREECLAMPSIAhttps://orcid.org/0000-0001-6995-4863БелоцерковцеваЛ. Д.BelotserkovtsevaL. D.

доктор медицинских наук, профессор

E-mail: info@surgut-kpc.ru

Doctor of Sciences (Medicine), Professor

E-mail: info@surgut-kpc.ru

https://orcid.org/0000-0002-0918-7129КоваленкоЛ. В.KovalenkoL. V.

доктор медицинских наук, профессор

E-mail: kovalenko_lv@surgu.ru

Doctor of Sciences (Medicine), Professor

E-mail: kovalenko_lv@surgu.ru

ПанкратовВ. В.PankratovV. V.

доктор медицинских наук, профессор, заместитель главного врача по родовспоможению и гинекологии

E-mail: docpankratov@mail.ru

Doctor of Sciences (Medicine), Professor, Deputy Chief Medical Officer for Obstetrics and Gynaecology

E-mail: docpankratov@mail.ru

https://orcid.org/0000-0001-8292-1820ИванниковС. Е.IvannikovS. E.

кандидат медицинских наук, доцент

E-mail: ivannikov_s@mail.ru

Candidate of Sciences (Medicine), Docent

E-mail: ivannikov_s@mail.ru

https://orcid.org/0000-0003-4415-7897МордовинаИ. И.MordovinaI. I.

кандидат медицинских наук, доцент

E-mail: mordovina_ii@surgu.ru

Candidate of Sciences (Medicine), Docent

E-mail: mordovina_ii@surgu.ru

КозловскаяО. В.KozlovskayaO. V.

заведующая инфекционным отделением

E-mail: surgutokb@surgutokb.ru

Head of the Department of Infectious Disease

E-mail: surgutokb@surgutokb.ru

ШумковА. М.ShumkovA. M.

врач-анестезиолог-реаниматолог

E-mail: surgutokb@surgutokb.ru

Anesthesiologist-Resuscitationist

E-mail: surgutokb@surgutokb.ru

ГаджиеваД. М.GadzhievaD. M.

ординатор

E-mail: d.m.gadzhieva@gmail.com

Medical Resident

E-mail: d.m.gadzhieva@gmail.com

Сургутский государственный университет, Сургут; Сургутский окружной клинический центр охраны материнства и детства, СургутРоссияSurgut State University, Surgut; Surgut District Clinical Center of Maternity and Childhood Health Care, SurgutRussian FederationСургутский государственный университет, СургутРоссияSurgut State University, SurgutRussian FederationСургутская окружная клиническая больница, СургутРоссияSurgut District Clinical Hospital, SurgutRussian Federation2023290620231622633Copyright © Белоцерковцева Л.Д., Коваленко Л.В., Панкратов В.В., Иванников С.Е., Мордовина И.И., Козловская О.В., Шумков А.М., Гаджиева Д.М., 20232023Белоцерковцева Л.Д., Коваленко Л.В., Панкратов В.В., Иванников С.Е., Мордовина И.И., Козловская О.В., Шумков А.М., Гаджиева Д.М.Belotserkovtseva L.D., Kovalenko L.V., Pankratov V.V., Ivannikov S.E., Mordovina I.I., Kozlovskaya O.V., Shumkov A.M., Gadzhieva D.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/650

Цель – оценка риска развития преэклампсии у беременных, инфицированных SARS-CoV-2, по результатам анализа за 2021 г. историй течения беременности и исходов родов 1 122 родоразрешенных женщин 3 групп: 52 беременных с подтвержденным SARS-CoV-2 и развившейся преэклампсией; 302 беременных с неподтвержденной инфекцией SARS-CoV-2 и развившейся преэклампсией; 768 беременных с подтвержденным SARS-CoV-2 и без преэклампсии. В группе пациенток с подтвержденным SARS-CoV-2 и развившейся преэклампсией в 2,5 раза чаще преобладала хроническая артериальная гипертензия по сравнению с беременными с преэклампсией с неподтвержденной инфекцией SARS-CoV-2 и в 10,4 раза – по сравнению с беременными без преэклампсии с подтвержденным SARS-CoV-2. Кроме того, вспомогательные репродуктивные технологии применялись чаще в 7,9 и 11,8 раз в группе беременных с подтвержденным SARS-CoV-2 и развившейся преэклампсией, чем в двух других группах беременных соответственно.Преждевременные роды, преждевременная отслойка нормально расположенной плаценты, родоразрешение путем кесарева сечения, асфиксия новорожденных чаще осложняли исходы родов в группах с преэклампсией.

The study aims to assess the risks for preeclampsia progression in pregnant women with SARS-CoV-2 based on the study obtained in 2021, which included the pregnancy course and outcome of 1 122 women divided into three groups. The groups were as following: 52 pregnant women with positive SARS-CoV-2 and preeclampsia, 302 women with negative SARS-CoV-2 and preeclampsia, and 768 pregnant women with positive SARS-CoV-2 and without preeclampsia. Chronic arterial hypertension prevailed in women with positive SARS-CoV-2 and preeclampsia by 2.5 times in comparison with those with negative SARS-CoV-2 and preeclampsia, and by 10.4 times in comparison with those with positive SARS-CoV-2 and without preeclampsia. Assisted reproductive technologies were used for pregnant women with positive SARS-CoV-2 and preeclampsia 7.9 and 11.8 times more frequently than for other groups of women. Women with preeclampsia suffered from premature birth, premature detachment of the placenta, cesarean delivery, and asphyxia of newborns at a higher rate.

преэклампсиябеременностьSARS-CoV-2пандемиякоронавирусная инфекцияpreeclampsiapregnancySARS-CoV-2pandemiccoronavirus infectionReferencesChen M., Zeng J., Liu X. et al. Changes in physiology and immune system during pregnancy and coronavirus infection: A review. Eur J Obstet Gynecol Reprod Biol. 2020;255:124–128.Chen M., Zeng J., Liu X. et al. Changes in physiology and immune system during pregnancy and coronavirus infection: A review. Eur J Obstet Gynecol Reprod Biol. 2020;255:124–128.Vousden N., Bunch K., Knight M. et al. Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study. PLoS One. 2021;16(1):e0244986.Vousden N., Bunch K., Knight M. et al. Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study. PLoS One. 2021;16(1):e0244986.Dawood F. S., Kittikraisak W., Patel A. et al. Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: A multisite prospective longitudinal cohort study. Lancet Infect Dis. 2021;21(1):97–106.Dawood F. S., Kittikraisak W., Patel A. et al. Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: A multisite prospective longitudinal cohort study. Lancet Infect Dis. 2021;21(1):97–106.Villar J., Ariff S., Gunier R. B. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817–826.Villar J., Ariff S., Gunier R. B. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817–826.Di Mascio D., Khalil A., Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: A systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107.Di Mascio D., Khalil A., Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: A systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107.Conde-Agudelo A., Romero R. SARS-COV-2 infection during pregnancy and risk of preeclampsia: A systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(1):68–89.e3.Conde-Agudelo A., Romero R. SARS-COV-2 infection during pregnancy and risk of preeclampsia: A systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(1):68–89.e3.Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press; 2010. 288 p.Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press; 2010. 288 p.Committee opinion No. 638: First-trimester risk assessment for early onset preeclampsia. Obstet Gynecol. 2015;126(3):e25–e27.Committee opinion No. 638: First-trimester risk assessment for early onset preeclampsia. Obstet Gynecol. 2015;126(3):e25–e27.Sotiriadis A., Hernandez-Andrade E., da Silva Costa F. et al. ISUOG Practice Guidelines: Role of ultrasound in screening for and follow-up of pre eclampsia. Ultrasound Obstet Gynecol. 2019;53(1):7–22.Sotiriadis A., Hernandez-Andrade E., da Silva Costa F. et al. ISUOG Practice Guidelines: Role of ultrasound in screening for and follow-up of pre eclampsia. Ultrasound Obstet Gynecol. 2019;53(1):7–22.Torres-Torres J., Martinez-Portilla R. J., Espino-Y-Sosa S. et al. Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: Analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico. Ultrasound Obstet Gynecol. 2022;59(1):76–82.Torres-Torres J., Martinez-Portilla R. J., Espino-Y-Sosa S. et al. Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: Analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico. Ultrasound Obstet Gynecol. 2022;59(1):76–82.Allotey J., Stallings E., Bonet M. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ. 2020;370:m3320.Allotey J., Stallings E., Bonet M. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ. 2020;370:m3320.Papageorghiou A. T., Deruelle P., Gunier R. B. et al. Preeclampsia and COVID-19: Results from the INTERCOVID Prospective Longitudinal Study. Am J Obstet Gynecol. 2021;225(3):289.e1–289.e17.Papageorghiou A. T., Deruelle P., Gunier R. B. et al. Preeclampsia and COVID-19: Results from the INTERCOVID Prospective Longitudinal Study. Am J Obstet Gynecol. 2021;225(3):289.e1–289.e17.Coronado-Arroyo J. C., Concepción-Zavaleta M. J., Zavaleta-Gutiérrez F. E. et al. Is COVID-19 a risk factor for severe preeclampsia? Hospital experience in a developing country. Eur J Obstet Gynecol Reprod Biol. 2021;256:502–503.Coronado-Arroyo J. C., Concepción-Zavaleta M. J., Zavaleta-Gutiérrez F. E. et al. Is COVID-19 a risk factor for severe preeclampsia? Hospital experience in a developing country. Eur J Obstet Gynecol Reprod Biol. 2021;256:502–503.Gheblawi M., Wang K., Viveiros A. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474.Gheblawi M., Wang K., Viveiros A. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474.Bhalla V., Blish C. A., South A. M. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens. 2021;35(10):935–939.Bhalla V., Blish C. A., South A. M. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens. 2021;35(10):935–939.Cui D., Liu Y., Jiang X. et al. Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta. Ultrasound Obstet Gynecol. 2021;57(2):248–256.Cui D., Liu Y., Jiang X. et al. Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta. Ultrasound Obstet Gynecol. 2021;57(2):248–256.Hecht J. L., Quade B., Deshpande V. et al. SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Mod Pathol. 2020;33(11):2092–2103.Hecht J. L., Quade B., Deshpande V. et al. SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Mod Pathol. 2020;33(11):2092–2103.Torres-Torres J., Espino-y-Sosa S., Poon L. C. et al. Increased levels of soluble fms-like tyrosine kinase-1 are associated with adverse outcome in pregnant women with COVID-19. Ultrasound Obstet Gynecol. 2022;59(2):202–208.Torres-Torres J., Espino-y-Sosa S., Poon L. C. et al. Increased levels of soluble fms-like tyrosine kinase-1 are associated with adverse outcome in pregnant women with COVID-19. Ultrasound Obstet Gynecol. 2022;59(2):202–208.Todros T., Masturzo B., De Francia S. COVID-19 infection: ACE2, pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2020;253:330.Todros T., Masturzo B., De Francia S. COVID-19 infection: ACE2, pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2020;253:330.Bloise E., Zhang J., Nakpu J. et al. Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. Am J Obstet Gynecol. 2021;224(3):298.e1–298.e8.Bloise E., Zhang J., Nakpu J. et al. Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. Am J Obstet Gynecol. 2021;224(3):298.e1–298.e8.Ouyang Y., Bagalkot T., Fitzgerald W. et al. Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and Furin. mSphere. 2021;6(2):e00250-21.Ouyang Y., Bagalkot T., Fitzgerald W. et al. Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and Furin. mSphere. 2021;6(2):e00250-21.Taglauer E., Benarroch Y., Rop K. et al. Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads. Placenta. 2020;100:69–74.Taglauer E., Benarroch Y., Rop K. et al. Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads. Placenta. 2020;100:69–74.Argueta L. B., Lacko L. A., Bram Y. et al. SARS-CoV-2 infects syncytiotrophoblast and activates inflammatory responses in the placenta. bioRxiv. 2021. DOI 10.1101/2021.06.01.446676.Argueta L. B., Lacko L. A., Bram Y. et al. SARS-CoV-2 infects syncytiotrophoblast and activates inflammatory responses in the placenta. bioRxiv. 2021. DOI 10.1101/2021.06.01.446676.Verma S., Joshi C. S., Silverstein R. B. et al. SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. Med. 2021;2(5):575–590.e5.Verma S., Joshi C. S., Silverstein R. B. et al. SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. Med. 2021;2(5):575–590.e5.Rana S., Lemoine E., Granger J. P. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–1112.Rana S., Lemoine E., Granger J. P. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–1112.Beys-da-Silva W. O., da Rosa R. L., Santi L. et al. The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection. Biochim Biophys Acta Mol Basis Dis. 2021;1867(3):165999.Beys-da-Silva W. O., da Rosa R. L., Santi L. et al. The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection. Biochim Biophys Acta Mol Basis Dis. 2021;1867(3):165999.Giuliani F., Oros D., Gunier R. B. et al. Effects of prenatal exposure to maternal COVID-19 and perinatal care on neonatal outcome: Results from the INTERCOVID Multinational Cohort Study. Am J Obstet Gynecol. 2022;227(3):488.e1–488.e17.Giuliani F., Oros D., Gunier R. B. et al. Effects of prenatal exposure to maternal COVID-19 and perinatal care on neonatal outcome: Results from the INTERCOVID Multinational Cohort Study. Am J Obstet Gynecol. 2022;227(3):488.e1–488.e17.

The authors declare that there are no conflicts of interest present.